Post-marketing surveillance of radium-223 chloride in Japanese patients with castration-resistant prostate cancer with bone metastasis—final analysis of 3-year extended follow-up focusing on bone fractures
Compared with existing reference data, there was no obvious increase in the incidence of clinical fractures in Japanese patients with mCRPC who were treated with radium-223 under clinical practice. As is already well known for androgen deprivation, BMAs may also be useful in reducing bone fracture after radium-223.
Authors
- Haruka Kakiuchi
- Shunji Takahashi (ORCID: https://orcid.org/0000-0002-5031-1953)
- Toshiyuki Sunaya
- Makoto Hosono (ORCID: https://orcid.org/0000-0001-8040-3245)
- Hirotsugu Uemura (ORCID: https://orcid.org/0000-0002-3665-9523)
- Yusuke Matsuba
- Naoya Masumori (ORCID: https://orcid.org/0000-0001-6324-0739)
- Yoshiyuki Kakehi (ORCID: https://orcid.org/0000-0002-4039-9066)
- Seigo Kinuya (ORCID: https://orcid.org/0000-0002-4495-4872)
- Masatoshi Adachi
- Kako Shimotsumagari
Institutions
- Kanazawa University (JP)
- Sapporo Medical University (JP)
- Santen (Japan) (JP)
- Kagawa University (JP)
- Veterans Health Administration (US)
- Netherlands Pharmacovigilance Centre Lareb (NL)
- Bayer (Japan) (JP)
- Japanese Foundation For Cancer Research (JP)
- Kindai University (JP)
Publication Details
- Journal
- International Journal of Clinical Oncology
- Published
- 2025-08-08
- DOI
- https://doi.org/10.1007/s10147-025-02846-7
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Bristol-Myers Squibb
- Novartis
- Takeda Pharmaceutical Company
- Taiho Pharmaceutical
- Daiichi-Sankyo
- Eisai
- Astellas Pharma
- Ono Pharmaceutical
- Chugai Pharmaceutical
- MSD K.K.
- Bayer Yakuhin
- Sanofi K.K.